rss
Thorax 1998;53:197-199 doi:10.1136/thx.53.3.197
  • Science matters

Gene therapy for cystic fibrosis: which postman, which box?

  1. Peter G Middletona,
  2. Eric W F W Altonb
  1. aDepartment of Respiratory Medicine, Westmead Hospital, Westmead, NSW 2145, Australia, bIon Transport Unit, National Heart and Lung Institute, London SW3 6LY, UK
  1. Dr P G Middleton.

    Abstract

    Since 1989 when the gene responsible for cystic fibrosis was cloned and designated the cystic fibrosis transmembrane conductance regulator (CFTR) gene, considerable progress has been made in the development of gene therapy for this disease. Clinical trials have already been performed using cationic liposome and adenoviral based gene transfer systems, measuring the safety and efficacy of this new form of treatment, with variable results to date. These two approaches and the current progress in airway gene delivery are discussed.

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.